Picard Medical (NYSEAMERICAN:PMI): 10.80% Decline | Catalysts and Risks
Key Takeaways
- The October 14 screen showed Picard Medical (NYSEAMERICAN:PMI) at USD 13.88, down 10.80% for the session. Turnover was 41,782 shares; market capitalization stood at USD 32 million, and its relative strength index (RSI) was 72.7.
- Parent company of SynCardia and its Total Artificial Heart, Picard Medical shed 10.80% to USD 13.88. Only 41,782 shares traded, and the session began with an 11.22% gap down.
- The RSI reading of 72.7 is in overbought territory, and the company completed a 1-for-50 reverse split on July 31 with second-quarter revenue up 39% to about USD 3.0 million and a net loss of about USD 5.7 million.
- Market value stands at USD 32 million; no company announcement dated October 14 was identified in the reviewed material.
Main Drivers and Recent Developments
Picard Medical, parent of SynCardia Systems, maker of the Total Artificial Heart, closed October 14 at USD 13.88, down 10.80% after an 11.22% opening gap. The reviewed company filings and wire releases did not identify an announcement dated October 14. Trading volume was 41,782 shares, or 0.1 times average at capture. RSI at 72.7 was in overbought territory, suggesting a pullback in a stock that had previously rallied; the earlier screen also showed a 7.31% pre-market decline on October 14.
Trading Metrics and Market Context
The company completed a 1-for-50 reverse split on July 31, second-quarter revenue rose 39% to about USD 3.0 million and the net loss narrowed 16% to about USD 5.7 million. Full-year 2025 revenue was USD 4.9 million with a negative gross margin and year-end cash of USD 11.5 million. The USD 32 million market value is about 2.7 times annualized quarterly revenue of roughly USD 12 million, based on a simple calculation. Using the reported percentage move, the prior close is estimated near USD 15.56, so the day's decline is about USD 1.68 a share. Shares opened 11.22% below the prior close and then lost a further 0.59% relative to the opening price, which helps separate the opening gap from later selling. Trading volume was 41,782 shares, 0.1 times average at the capture time, while the trading session was still in progress, and the RSI of 72.7 is labeled up, overbought.
Principal Risks and Upcoming Catalysts
Overbought momentum, a negative gross margin and recurring equity raises make the stock volatile. Near-term items to track include financing, device sales and regular-session volume. This discussion is for informational purposes only and is not investment advice. Wednesday's September inflation report was stronger than expected; the 10-year Treasury yield moved to roughly 5.28%, while the 30-year yield reached about 5.59%. Following the hotter inflation print, markets weighed the possibility that the Federal Reserve could raise rates again at its October 27 and 28 meeting. Debt-funded AI-infrastructure shares came under pressure after CoreWeave's bond yields surged and Elon Musk replied 'Yikes' to a warning about them; CoreWeave fell 13%. Bank of America declined after a penalty exceeding USD 1.2 billion tied to money-laundering safeguards, while BlackRock advanced after beating expectations.
Current Market Assessment
October 14 weakness spanned AI-infrastructure companies, banks reacting to earnings and thinly traded micro-caps, while hotter inflation data added to market pressure. For Picard Medical (NYSEAMERICAN:PMI), the decline occurred alongside a pullback from an overbought level in a micro-cap. A single session cannot establish whether the move will reverse or extend, so a firmer view should wait for relevant filings and another trading session. Upcoming items to monitor include financing, device sales and regular-session volume. The screen reflects an unfinished session; treat these figures as a snapshot and confirm them against the underlying disclosures.






Please wait processing your request...